EE05307B1 - Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks - Google Patents

Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks

Info

Publication number
EE05307B1
EE05307B1 EEP200300547A EEP200300547A EE05307B1 EE 05307 B1 EE05307 B1 EE 05307B1 EE P200300547 A EEP200300547 A EE P200300547A EE P200300547 A EEP200300547 A EE P200300547A EE 05307 B1 EE05307 B1 EE 05307B1
Authority
EE
Estonia
Prior art keywords
broad
spectrum
pharmaceutical composition
protease inhibitors
hiv protease
Prior art date
Application number
EEP200300547A
Other languages
English (en)
Inventor
Louis Nestor Ghislain Surleraux Dominique
Marie Helene Vendeville Sandrine
Gaston Verschueren Wim
T.M.M.G De Bethune Marie-Pierre
Augustinus De Kock Herman
Tahri Abdellah
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Publication of EE200300547A publication Critical patent/EE200300547A/et
Publication of EE05307B1 publication Critical patent/EE05307B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200300547A 2001-05-11 2002-05-10 Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks EE05307B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201732 2001-05-11
PCT/EP2002/005212 WO2002092595A1 (en) 2001-05-11 2002-05-10 Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200300547A EE200300547A (et) 2004-02-16
EE05307B1 true EE05307B1 (et) 2010-06-15

Family

ID=8180286

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300547A EE05307B1 (et) 2001-05-11 2002-05-10 Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks

Country Status (32)

Country Link
US (2) US7622490B2 (et)
EP (1) EP1387842B1 (et)
JP (1) JP4467889B2 (et)
KR (1) KR100878853B1 (et)
CN (1) CN100549007C (et)
AP (1) AP1652A (et)
AR (1) AR035970A1 (et)
AT (1) ATE429431T1 (et)
AU (1) AU2002310818B2 (et)
BG (1) BG66350B1 (et)
BR (1) BR0209594A (et)
CA (1) CA2444895C (et)
CY (1) CY1109247T1 (et)
CZ (1) CZ304524B6 (et)
DE (1) DE60232067D1 (et)
DK (1) DK1387842T3 (et)
EA (1) EA009590B1 (et)
EE (1) EE05307B1 (et)
ES (1) ES2325809T3 (et)
HK (1) HK1062912A1 (et)
HR (1) HRP20031026B1 (et)
HU (1) HUP0400438A3 (et)
IL (1) IL158093A0 (et)
MX (1) MXPA03010258A (et)
NO (1) NO326883B1 (et)
NZ (1) NZ529250A (et)
OA (1) OA13134A (et)
PL (1) PL209029B1 (et)
PT (1) PT1387842E (et)
SK (1) SK287952B6 (et)
WO (1) WO2002092595A1 (et)
ZA (1) ZA200307799B (et)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2003064406A1 (en) 2002-01-07 2003-08-07 Sequoia Pharmaceuticals Resistance-repellent retroviral protease inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0414916A (pt) * 2003-09-30 2006-11-07 Tibotec Pharm Ltd métodos para a preparação de compostos de sulfonamida de benzoxazol e intermediários dos mesmos
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
UA85567C2 (en) 2003-12-23 2009-02-10 Тиботек Фармасьютикелз Лтд. Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
AU2004309122B2 (en) 2003-12-23 2011-07-21 Janssen Sciences Ireland Unlimited Company Process for the preparation of (3R,3aS,6AR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
CA2566340C (en) * 2004-05-07 2014-05-06 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
BRPI0607827B8 (pt) 2005-02-25 2021-05-25 Janssen R & D Ireland composto precursor de inibidor de protease, processo para a produção do referido composto e seu uso
AR053845A1 (es) * 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
EP0445926B1 (en) 1990-03-09 1996-08-21 Milliken Research Corporation Organic materials having sulfonamido linked poly(oxyalkylene) moieties and their preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE154800T1 (de) * 1992-08-25 1997-07-15 Searle & Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
ES2127938T3 (es) * 1993-08-24 1999-05-01 Searle & Co Hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas.
DK0721331T3 (da) 1993-10-01 2002-02-11 Astrazeneca Ab Fremgangsmåde
CA2210889C (en) 1995-01-20 2007-08-28 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
PL184771B1 (pl) 1995-03-10 2002-12-31 Searle & Co Związek stanowiący hydroksyetyloaminosulfonamid pirolidynokarbonyloaminokwasu, kompozycja zawierająca ten związek, jego zastosowanie do wytwarzania kompozycji do leczenia infekcji retrowirusowej i sposób zapobiegania replikacji retrowirusa in vitro
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
AU7722296A (en) * 1995-11-15 1997-06-05 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
EE03902B1 (et) 1996-05-20 2002-12-16 Janssen Pharmaceutica N.V. Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
ATE241969T1 (de) 1997-03-26 2003-06-15 Janssen Pharmaceutica Nv Tabletten mit einem kern, der mit einem pilzbekämpfungsmittel und einem polymeren beschichtet ist
GB9717849D0 (en) 1997-08-23 1997-10-29 Seal Sands Chemicals Limited Preparation of pyridene derivatives
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
ID25551A (id) 1997-12-24 2000-10-12 Vertex Pharma Bahan baku obat penghambat protease aspartil
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
DK1088098T4 (en) 1998-06-23 2015-09-14 Us Of America Represented By The Secretary Dept Of Health And Human Services Fitnessassay and methods for reducing HIV resistance to therapy
AU4828199A (en) * 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
PL367084A1 (en) * 2001-04-09 2005-02-21 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors

Also Published As

Publication number Publication date
JP4467889B2 (ja) 2010-05-26
CA2444895C (en) 2011-02-15
US20100029632A1 (en) 2010-02-04
HRP20031026A2 (en) 2005-10-31
AP1652A (en) 2006-08-11
CA2444895A1 (en) 2002-11-21
BG108309A (bg) 2004-12-30
PL366780A1 (en) 2005-02-07
KR100878853B1 (ko) 2009-01-15
US20040106661A1 (en) 2004-06-03
ES2325809T3 (es) 2009-09-18
SK287952B6 (sk) 2012-06-04
OA13134A (en) 2006-12-13
HUP0400438A3 (en) 2007-08-28
US7863306B2 (en) 2011-01-04
EP1387842A1 (en) 2004-02-11
PT1387842E (pt) 2009-07-20
CZ304524B6 (cs) 2014-06-18
AU2002310818B2 (en) 2007-12-13
US7622490B2 (en) 2009-11-24
NO326883B1 (no) 2009-03-09
DE60232067D1 (de) 2009-06-04
JP2004534757A (ja) 2004-11-18
EA009590B1 (ru) 2008-02-28
NO20034988D0 (no) 2003-11-10
AP2003002904A0 (en) 2003-12-31
BR0209594A (pt) 2004-03-30
ATE429431T1 (de) 2009-05-15
PL209029B1 (pl) 2011-07-29
IL158093A0 (en) 2004-03-28
SK14902003A3 (sk) 2004-07-07
AR035970A1 (es) 2004-07-28
HRP20031026B1 (en) 2012-07-31
CY1109247T1 (el) 2014-07-02
MXPA03010258A (es) 2005-03-07
WO2002092595A1 (en) 2002-11-21
HUP0400438A2 (hu) 2004-08-30
EE200300547A (et) 2004-02-16
NZ529250A (en) 2005-05-27
EP1387842B1 (en) 2009-04-22
CN100549007C (zh) 2009-10-14
ZA200307799B (en) 2005-03-30
BG66350B1 (bg) 2013-08-30
CN1507446A (zh) 2004-06-23
HK1062912A1 (en) 2004-12-03
EA200301234A1 (ru) 2004-04-29
CZ20033290A3 (cs) 2004-05-12
DK1387842T3 (da) 2009-08-10
KR20040022417A (ko) 2004-03-12

Similar Documents

Publication Publication Date Title
EE200300381A (et) Laiaspektrilised 2-(asendatud amino)bensotiasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende valmistamismeetod ja kasutamine, farmatseutilinekompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
EE200300547A (et) Laiaspektrilised 2-aminobensoksasoolsulfoonamiidid kui HIV proteaasi inhibiitorid, nende kasutamine, farmatseutiline kompositsioon ja meetod retroviiruse replikatsiooni inhibeerimiseks
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
BR0112292A (pt) Composto, composição farmacêutica, método para tratar ou prevenir disfunções tromboembólicas e uso de um composto
DK1564210T3 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
NO20030381D0 (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
HUP0400194A3 (en) Imidazolidindion derivatives as metalloproteinase inhibitors, their use and pharmaceutical compositions containing them
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
EE200300327A (et) Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
DK1399444T3 (da) Nye heterocycliske forbindelser, fremgangsmåde til fremstilling af samme samt anvendelse deraf som lægemidler, især som antibakterielle midler
EE200300369A (et) Atsüülitud indanüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
NO20005224D0 (no) BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse
HUP0400175A2 (en) Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity, their use and pharmaceutical compositions containing them
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
BRPI0414548A (pt) derivados de 2-piridona inibidores de elastase de neutrófilo e seu uso
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20042916L (no) HIV integrase inhibitorer
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
NO20023643L (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem

Legal Events

Date Code Title Description
HE1A Change of address
HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20160510